Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed and fasted conditions and in subjects with Type 2 Diabetes Mellitus under fasted conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Ligand Pharmaceuticals

Collaborators:

Beckloff Associates, Inc.
Medpace, Inc.